inclusion criteria: men or women aged 18 years and older at visit 1 (baseline/screening) women of child-bearing potential must have a negative urine pregnancy test at visit 1 (baseline/screening) must be confirmed positive for sars-cov-2 with rt-pcr testing of a nasal swab taken within 72 hours prior to randomization (first dose of study drug) must have a score ≤ 2 on the who ordinal scale for clinical improvement subject must be willing to refrain from any other intranasal instillations (e.g., medications, saline, etc.) for 24 hours after study medication dosing must be capable, in the opinion of the investigator, of providing informed consent to participate in the study.

inclusion criteria: men or women aged 18 years and older at visit 1 (baseline/screening) women of child-bearing potential must have a negative urine pregnancy test at visit 1 (baseline/screening) must be confirmed positive for sars-cov-2 with rt-pcr testing of a nasal swab taken within 72 hours prior to randomization (first dose of study drug) must have a score ≤ 2 on the who ordinal scale for clinical improvement subject must be willing to refrain from any other intranasal instillations (e.g., medications, saline, etc.) for 24 hours after study medication dosing must be capable, in the opinion of the investigator, of providing informed consent to participate in the study.

inclusion criteria: 1. men or women aged 18 years and older at visit 1 (baseline/screening) 2. women of child-bearing potential must have a negative urine pregnancy test at visit 1 (baseline/screening) 3. must be confirmed positive for sars-cov-2 with rt-pcr testing of a nasal swab taken within 72 hours prior to randomization (first dose of study drug) 4. must have a score ≤ 2 on the who ordinal scale for clinical improvement 5. subject must be willing to refrain from any other intranasal instillations (e.g., medications, saline, etc.) for 24 hours after study medication dosing 6. must be capable, in the opinion of the investigator, of providing informed consent to participate in the study.

inclusion criteria: 1. men or women aged 18 years and older at visit 1 (baseline/screening) 2. women of child-bearing potential must have a negative urine pregnancy test at visit 1 (baseline/screening) 3. must be confirmed positive for sars-cov-2 with rt-pcr testing of a nasal swab taken within 72 hours prior to randomization (first dose of study drug) 4. must have a score ≤ 2 on the who ordinal scale for clinical improvement 5. subject must be willing to refrain from any other intranasal instillations (e.g., medications, saline, etc.) for 24 hours after study medication dosing 6. must be capable, in the opinion of the investigator, of providing informed consent to participate in the study.